Please ensure Javascript is enabled for purposes of website accessibility

Here's Why OPKO Health Dropped as Much as 23% Today

By Maxx Chatsko - May 18, 2018 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced that a potential-packed product may not be covered by government insurance programs.

What happened

Shares of OPKO Health (OPK -4.05%) suffered a free fall today, losing as much as 23%. The drop occurred after the company announced that a crucial Medicare Administrative Contractor issued a draft local coverage determination (LCD) for the highly anticipated 4Kscore diagnostic test. That's a mouthful, but the implications are simple.

If the draft LCD is finalized, then the 4Kscore product would not be covered by Medicare. If it's not covered by the government insurance program, then the product's market potential -- viewed as a significant determinant in OPKO Health's future -- will be severely diluted. 

The draft LCD is subject to a comment period until July 5 -- and the company has pledged to submit comments in an attempt to rescue the product's potential. But as of 11:11 a.m. EDT, the stock had settled to a 18.4% loss.

A finger pointing to a chart showing losses on a touchscreen.

Image source: Getty Images.

So what

The 4Kscore test is used to help influence treatment decisions regarding the diagnosis of prostate cancer in men. If a man has an elevated level of prostate specific antigen (PSA) in his blood, then it may be necessary to conduct a tissue biopsy to determine the next steps in treatment, if any. But biopsies are invasive and expensive, and using PSA levels as the sole metric to determine if a biopsy is required has led to many unnecessary procedures.

That's where the 4Kscore test comes in. It's used after reading PSA levels and before a biopsy, has robust accuracy rates, and has been included in various cancer and urology guidelines in the United States and Europe since 2015. Investors thought it could represent a billion-dollar market opportunity, but it's been off to a slow commercial start.

Today's news doesn't help the product's prospects. That's especially true considering the Medicare Administrative Contractor that issued the draft LCD is Novitas. It handles nearly all of OPKO Health's Medicare reimbursement requests for 4Kscore tests, as both the company's diagnostic lab and Novitas' jurisdiction are in New Jersey. Losing coverage under Medicare would be a significant setback for the diagnostic test. 

Now what

Investors can expect OPKO Health to vigorously fight for a positive LCD recommendation from Novitas, but it may be more complicated than that. The decision to recommend noncoverage for the 4Kscore test was made to sync up with recommendations from another major Medicare Administrative Contractor, as reported in the company's annual filing earlier this year. In other words, this situation could be a little more complicated than simply changing minds during the current comment period. Given the company's history of struggles, investors should continue to avoid this stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
$2.48 (-4.05%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.